Compound | IC50 | ||
---|---|---|---|
α4β2 nAChRs | α3β4 nAChRs | ||
nM | |||
Sazetidine-A | |||
0-min | >10,000 | >10,000 | |
Pretreatment | |||
10-min | 26 ± 7 | >10,000 | |
Pretreatment | |||
DHβE | |||
0-min | 1400 ± 200 | 160,000 ± 20,000 | |
Pretreatment | |||
10-min | 1400 ± 300 | 130,000 ± 58,000 | |
Pretreatment | |||
Varenicline | |||
0-min | >5,000 | Not Tested | |
Pretreatment | |||
10-min | 50 ± 14 | Not Tested | |
Pretreatment | |||
(−)-Nicotine | |||
0-min | —a | — | |
Pretreatment | |||
10-min | 180 ± 70 | Not Tested | |
Pretreatment |
|
|
↵ a Dashes indicate that nicotine is a full agonist in those conditions.